Previous 10 | Next 10 |
2023-11-14 17:26:35 ET More on Absci Absci, Almirall partner on dermatologic drug development Seeking Alpha’s Quant Rating on Absci Historical earnings data for Absci Financial information for Absci For further details see: Absci GAAP EPS o...
Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties Unveiled AI drug creation pipeline of four wholly-owned assets VANCOUVER, Wash. and NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Abs...
2023-11-14 07:33:17 ET Spanish drugmaker Almirall and biotech Absci ( NASDAQ: ABSI ) have forged a partnership to develop AI-designed therapeutics for chronic dermatological diseases. Leveraging its de novo generative AI technology, Absci ( ABSI ) will develop and commer...
VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, and Almirall S.A. ( BME: ALM ) , a global biopharmaceutical company focused on medical dermatology, today announced a drug discove...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Absci Corporation (ABSI) is expected to report $-0.23 for Q3 2023
VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day on Wednesday, October 4 th , 2023. The program will begin at 9:00 a.m. Eastern Time...
2023-09-20 07:47:47 ET More on Exscientia and AI drug discovery Seeking Alpha’s Quant Rating on Exscientia Exscientia Is Worth The AI-Driven Speculation Exscientia gains as enrollments begin for cancer trial AI to represent 11% of healthcare budgets in...
VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on Wednesday, October 4 th , 2023 in New York City. The program will begin at 9:00 a.m. Easter...
2023-09-04 12:00:00 ET More on AI Cathie Wood's 'Big Ideas 2023' sees Artificial Intelligence as the future Artificial intelligence is a '1995 moment' for tech. That could push stocks even higher Apple CEO Tim Cook says artificial intelligence 'is a major focus of ou...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday,...
VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stoc...
VANCOUVER, Wash. and NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Morgan Stanley 3 rd Annual Life Sciences AI Summit on June 26-27 in New York, ...